We Should Treat Fewer Patients with Elevated Intraocular Pressure Now That We Know the Results of the Ocular Hypertension Treatment Study

Archives of Ophthalmology

Volumn 122, Issue 3, 2004, Pages 378-379

  Jampel, Henry D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

CLINICAL PRACTICE; CLINICAL TRIAL; CORNEA; FOLLOW UP; GLAUCOMA; HIGH RISK PATIENT; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THICKNESS; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL FIELD; VISUAL FIELD DEFECT;

ANTIHYPERTENSIVE AGENTS; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION;

EID: 1542348334     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.3.378     Document Type: Review

References (5)

1. Cioffi GA, Liebmann JM. Translating the OHTS results into clinical practice. J Glaucoma. 2002;11: 375-377.
2. Palmberg P. Answers from the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2002; 120:829-830.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
4. Coleman A. Applying evidence-based medicine in ophthalmic practice. Am J Ophthalmol. 2002; 134:599.
5. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.